S8 Bonus Episode: ¡No Más Melanomas! – Updates in the Treatment of Cutaneous Melanoma

Melanoma treatment has advanced significantly over the past decade, and it continues to evolve. In this special Melanoma Monday episode, we are joined by Kendra Rodriguez, PGY2 Oncology Pharmacy Resident at UW Medical Center / Fred Hutchinson Cancer Center, to explore where we are now—and what’s ahead.

From the growing role of neoadjuvant therapy to the arrival of TIL-based options like lifileucel, Kendra walks through recent data and shares how care teams can start preparing for what’s next. You’ll hear about clinical trials like NADINA and SWOG S1801, what it takes to manage complex therapies, and how to engage patients through thoughtful communication and collaboration.

CE Activity Description:
The purpose of this CE activity is to describe the pathophysiology and literature behind the shift of pharmacotherapeutic management to the neoadjuvant setting in resectable cutaneous melanoma. As novel mechanisms have been sought after and approved within this disease state, attention will be given to assess the clinical utility of the first-in-class tumor-infiltrating lymphocyte, lifileucel, in addition to its logistical considerations requiring multidisciplinary coordination.

Learning Objectives:

• Summarize the pathophysiology behind neoadjuvant treatment in cutaneous melanoma and the literature supporting its use
• Discuss the novel agent lifileucel for its efficacy in cutaneous melanoma treatment and the logistics related to its use

Disclosures:
No relevant financial relationships for the following faculty and reviewers:
• Kendra Gee-Rodriguez, PharmD
• Ginger Blackmon, PharmD
• Daisy Doan, PharmD

Claim credit: https://www.lecturepanda.com/r/CutaneousMelanoma

Download Episode